Disclosures for "Disparities in the Evaluation and Treatment of Pediatric Migraine in the Emergency Department Using a Language-learning Model"
-
The institution of Ms. Kellier has received research support from National Institute of Neurological Disorders and Stroke.
-
Dr. Anto has nothing to disclose.
-
Dr. Boland has received research support from NIH/University of Pennsylvania.
-
Dr. Press has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Marinus Pharmaceuticals. Dr. Press has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Law Firms. Dr. Press has received research support from Marinus Pharmaceuticals. Dr. Press has received research support from Pediatric Epilepsy Research Foundation. Dr. Press has received research support from NIH.
-
Dr. Hughes has nothing to disclose.
-
Mrs. Ostapenko has nothing to disclose.
-
Dr. Farrar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharma. Dr. Farrar has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for PharamcoEpidemiology and Drug Safety. The institution of Dr. Farrar has received research support from Food and Drug Administration . The institution of Dr. Farrar has received research support from NIH .
-
The institution of Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Dr. Szperka has received research support from Pfizer. Dr. Szperka has received research support from FDA.